Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01808222 · ClinicalTrials.gov registry record · Phase 2
FACBC for Recurrent Prostate Cancer
A Phase 2 study, sponsored by David M. Schuster, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01808222: Completed Phase 2 study, sponsored by David M. Schuster, MD.
NCT01808222 is a Phase 2 study that has completed, run by David M. Schuster, MD. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01808222, a Phase 2 study, has completed, sponsored by David M. Schuster, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The investigators will perform a study with 25 patients in whom the investigators have a strong suspicion of prostate cancer that has returned to the body after having an initial treatment. The major goal of the investigation is to see whether anti-\[18F\] FACBC PET-CT and MRI imaging individually will be useful in the detection of local and extraprostatic recurrence of prostate cancer. Routine blood test will be done on the day of the FACBC scan and one week later as required by the FDA. All patients will undergo biopsy of the prostate as clinically appropriate per standard of care. If either the FACBC or MRI scans indicate cancer recurrence, the subject's cancer site(s) will also be biopsied as clinically appropriate.
Interventions
- DRUG FACBC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-11 |
| Est. Completion | 2017-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01808222
The ClinicalTrials.gov registry entry for NCT01808222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David M. Schuster, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FACBC is the first listed.
NCT01808222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01808222 about?
NCT01808222 is a clinical study titled "FACBC for Recurrent Prostate Cancer". The investigators will perform a study with 25 patients in whom the investigators have a strong suspicion of prostate cancer that has returned to the body after having an initial treatment. The major goal of the investigation is to see whether anti-\[18F\] FACBC PET-CT and MRI imaging individually w...
What is the current status of trial NCT01808222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2013-11. Estimated completion is 2017-09-13.
What interventions are being tested in trial NCT01808222?
The interventions under investigation include: FACBC (DRUG).
Who is sponsoring clinical trial NCT01808222?
This trial is sponsored by David M. Schuster, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.